Table 5.6a

Immunosuppression Use for Induction, 1994 to 2003

Recipients with Kidney Transplants

	Year of Transplant
	1994	1995	1996	1997	1998	1999	2000	2001	2002	2003
Transplants	10,646	11,073	11,389	11,696	12,432	12,737	13,573	14,239	14,774	15,129
Tx With Immunosuppression Info	10,061	10,828	11,150	11,604	12,318	12,448	13,201	14,080	14,594	14,760
No Induction Drugs Recorded	75.3%	73.3%	63.2%	65.7%	61.1%	53.0%	47.8%	42.6%	35.3%	30.1%
Drugs	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
ALG
ATG/NRATG/NRATS	0.4%	1.4%	15.3%	17.3%	12.2%	6.6%	3.2%	2.5%	1.9%	1.1%
OKT3	24.3%	25.1%	21.4%	17.7%	10.0%	3.9%	1.8%	0.8%	0.9%	0.4%
Thymoglobulin	0.0%	0.0%	0.0%	0.0%	0.2%	4.9%	10.1%	17.1%	25.7%	33.7%
Zenapax	0.0%	0.1%	0.2%	0.2%	13.0%	16.5%	13.2%	14.4%	12.9%	12.6%
Simulect	0.0%	0.2%	0.6%	0.1%	5.0%	17.2%	26.5%	25.2%	26.3%	21.6%
Campath	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	3.5%

Source: OPTN/SRTR Data as of May 3, 2004.

Induction drugs include any reported antilymphocyte antibodies and antibodies directed against lymphocyte receptors.